{"schema_version":"secwatch.filing_event.v1","accession":"0000318154-24-000033","form_type":"8-K","ticker":"AMGN","cik":"0000318154","company_name":"AMGEN INC","filed_at":"2024-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.484528+00:00","generated_at":"2026-05-31T12:44:19.518416+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Amgen Q2 2024 revenue up 20% to $8.4B, but GAAP EPS falls 46% to $1.38","bullets":["Total revenues $8.4B, up 20% YoY; product sales up 20% (5% ex-Horizon), driven by 26% volume growth.","GAAP EPS $1.38 (down 46%); non-GAAP EPS $4.97 (down 1%); GAAP operating margin 23.7% vs 40.2%.","Free cash flow $2.2B, vs $3.8B in Q2 2023, due to timing of tax payments.","Twelve products had double-digit sales growth; rare disease sales $1.1B; Repatha, Prolia, TEZSPIRE among leaders.","Non-GAAP operating income $3.9B (up 11%); operating margin 48.2%, down 4.4pp year-over-year."],"urls":{"canonical":"https://secwatch.observer/filing/0000318154-24-000033","json":"https://secwatch.observer/filing/0000318154-24-000033.json","markdown":"https://secwatch.observer/filing/0000318154-24-000033.md","text":"https://secwatch.observer/filing/0000318154-24-000033.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/318154/000031815424000033/0000318154-24-000033-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/318154/000031815424000033/amgn-20240806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T12:44:19.518416+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}